vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and KAMADA LTD (KMDA). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $47.0M, roughly 1.0× KAMADA LTD). KAMADA LTD runs the higher net margin — 11.3% vs -4.8%, a 16.0% gap on every dollar of revenue. On growth, KAMADA LTD posted the faster year-over-year revenue change (12.6% vs -47.3%). Over the past eight quarters, KAMADA LTD's revenue compounded faster (12.0% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.
IRWD vs KMDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $47.0M |
| Net Profit | $-2.3M | $5.3M |
| Gross Margin | — | 42.0% |
| Operating Margin | 14.3% | 16.6% |
| Net Margin | -4.8% | 11.3% |
| Revenue YoY | -47.3% | 12.6% |
| Net Profit YoY | -200.9% | 37.1% |
| EPS (diluted) | $0.01 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | — | ||
| Q3 25 | $122.1M | $47.0M | ||
| Q2 25 | $85.2M | $44.8M | ||
| Q1 25 | $41.1M | $44.0M | ||
| Q4 24 | $90.5M | — | ||
| Q3 24 | $91.6M | $41.7M | ||
| Q2 24 | $94.4M | $42.5M | ||
| Q1 24 | $74.9M | $37.7M |
| Q4 25 | $-2.3M | — | ||
| Q3 25 | $40.1M | $5.3M | ||
| Q2 25 | $23.6M | $7.4M | ||
| Q1 25 | $-37.4M | $4.0M | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $3.6M | $3.9M | ||
| Q2 24 | $-860.0K | $4.4M | ||
| Q1 24 | $-4.2M | $2.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | 42.0% | ||
| Q2 25 | — | 42.3% | ||
| Q1 25 | — | 47.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 41.3% | ||
| Q2 24 | — | 44.6% | ||
| Q1 24 | — | 44.4% |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 61.8% | 16.6% | ||
| Q2 25 | 53.2% | 15.8% | ||
| Q1 25 | -70.7% | 17.7% | ||
| Q4 24 | 34.8% | — | ||
| Q3 24 | 28.0% | 12.7% | ||
| Q2 24 | 26.5% | 13.3% | ||
| Q1 24 | 14.7% | 10.7% |
| Q4 25 | -4.8% | — | ||
| Q3 25 | 32.8% | 11.3% | ||
| Q2 25 | 27.7% | 16.5% | ||
| Q1 25 | -90.9% | 9.0% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 4.0% | 9.3% | ||
| Q2 24 | -0.9% | 10.4% | ||
| Q1 24 | -5.6% | 6.3% |
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.23 | $0.09 | ||
| Q2 25 | $0.14 | $0.13 | ||
| Q1 25 | $-0.23 | $0.07 | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.02 | $0.07 | ||
| Q2 24 | $-0.01 | $0.08 | ||
| Q1 24 | $-0.03 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $72.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $265.2M |
| Total Assets | $396.9M | $377.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | — | ||
| Q3 25 | $140.4M | $72.0M | ||
| Q2 25 | $92.9M | $66.0M | ||
| Q1 25 | $108.5M | $76.3M | ||
| Q4 24 | $88.6M | — | ||
| Q3 24 | $88.2M | $72.0M | ||
| Q2 24 | $105.5M | $56.5M | ||
| Q1 24 | $121.5M | $48.2M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | — | ||
| Q3 25 | $-264.2M | $265.2M | ||
| Q2 25 | $-308.2M | $260.0M | ||
| Q1 25 | $-334.1M | $252.0M | ||
| Q4 24 | $-301.3M | — | ||
| Q3 24 | $-311.3M | $255.3M | ||
| Q2 24 | $-321.7M | $251.2M | ||
| Q1 24 | $-330.5M | $251.2M |
| Q4 25 | $396.9M | — | ||
| Q3 25 | $396.1M | $377.2M | ||
| Q2 25 | $342.9M | $368.2M | ||
| Q1 25 | $327.2M | $375.1M | ||
| Q4 24 | $350.9M | — | ||
| Q3 24 | $389.5M | $351.2M | ||
| Q2 24 | $395.6M | $351.0M | ||
| Q1 24 | $438.8M | $343.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $10.4M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.97× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | $10.4M | ||
| Q2 25 | $-15.1M | $8.0M | ||
| Q1 25 | $20.0M | $-513.0K | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $9.9M | $22.2M | ||
| Q2 24 | $33.5M | $14.0M | ||
| Q1 24 | $45.0M | $1.0M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | 1.97× | ||
| Q2 25 | -0.64× | 1.09× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | 5.75× | ||
| Q2 24 | — | 3.15× | ||
| Q1 24 | — | 0.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
